http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102208542-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1774 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
| filingDate | 2017-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102208542-B1 |
| titleOfInvention | An oral anti-obesity composition comprising GLP-1 and a gene carrier |
| abstract | The present invention relates to an oral composition for the prevention, treatment, or improvement of obesity, by binding Arginine 9 amino acids having cationic properties to the Fc portion C-terminal and condensing it with the GLP-1 gene having anionic properties in the body. It can effectively induce the expression of the GLP-1 gene, and when administered orally, the gene can be transferred to the small intestine by protecting the gene from degradation caused by the immune function of gastric acid and leukocytes, and when the gene is expressed in the small intestine Since the half-life was relatively long, the possibility of long-term therapeutic effect was confirmed. Through effective delivery of GLP-1, it is expected to be useful for preventing, treating, or improving obesity. |
| priorityDate | 2017-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 213.